MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

MPM Bioimpact LLC reduced its stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 24.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,231,154 shares of the company's stock after selling 408,695 shares during the period. MPM Bioimpact LLC owned 2.90% of Repare Therapeutics worth $1,613,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Barclays PLC increased its stake in shares of Repare Therapeutics by 1,471.7% in the third quarter. Barclays PLC now owns 8,330 shares of the company's stock worth $29,000 after purchasing an additional 7,800 shares during the period. Vontobel Holding Ltd. raised its holdings in Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock valued at $46,000 after acquiring an additional 11,000 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Repare Therapeutics by 204.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after acquiring an additional 23,127 shares during the period. Stifel Financial Corp lifted its position in shares of Repare Therapeutics by 73.1% in the 4th quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock worth $117,000 after acquiring an additional 37,800 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Repare Therapeutics by 65.5% in the 4th quarter. Millennium Management LLC now owns 170,959 shares of the company's stock worth $224,000 after acquiring an additional 67,638 shares during the period. 85.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price objective on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 7th.

Repare Therapeutics Stock Up 1.5%

NASDAQ:RPTX traded up $0.02 during trading hours on Monday, hitting $1.36. 67,913 shares of the stock were exchanged, compared to its average volume of 259,976. The company's 50 day moving average is $1.17 and its two-hundred day moving average is $1.66. Repare Therapeutics Inc. has a twelve month low of $0.89 and a twelve month high of $4.29. The company has a market capitalization of $58.33 million, a P/E ratio of -0.68 and a beta of 0.85.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. On average, equities research analysts expect that Repare Therapeutics Inc. will post -2.04 EPS for the current year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.